German biotech firm Tubulis has raised €308 million in a record-breaking Collection C funding spherical, marking the most important Collection C ever closed by a European biotech and the largest financing for a personal antibody-drug conjugate (ADC) developer worldwide. The spherical was led by Venrock Healthcare Capital Companions, with participation from Wellington Administration and Ascenta Capital, alongside present traders together with Nextech Make investments, EQT Life Sciences, Frazier Life Sciences, Andera Companions, Deep Observe Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Companions, and HTGF.
Based in Munich, Tubulis specialises in creating uniquely matched ADCs that mix antibodies with potent medicine to focus on and destroy most cancers cells with excessive precision. The brand new funding will speed up the scientific improvement of its lead candidate, TUB-040, which targets NaPi2b, an antigen overexpressed in ovarian and lung cancers. At present beneath analysis in a Part I/IIa research, TUB-040 obtained Quick Observe designation from the U.S. FDA in 2024.
The contemporary capital may also advance Tubulis’ broader pipeline, together with TUB-030 and a number of preclinical programmes, in addition to broaden its proprietary ADC platform applied sciences. These improvements intention to unlock new therapeutic prospects and enhance outcomes for sufferers with stable tumours.
“This landmark financing spherical displays the deep conviction these international healthcare traders have in Tubulis and the disruptive potential of our ADC platforms,” stated Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. “With TUB-040 progressing within the clinic and first information to be shared in a late-breaking oral presentation at ESMO, we’re able to broaden into earlier therapy strains, whereas persevering with to innovate throughout our pipeline and expertise platforms. The brand new funding empowers us to execute on our imaginative and prescient of making actually differentiated antibody-drug conjugates which are tailor-made to the biology of stable tumours and might ship superior therapeutic worth to sufferers.”
HTGF (Excessive-Tech Gründerfonds), one among Tubulis’ earliest backers, renewed and expanded its dedication on this spherical. The investor co-led Tubulis’ Collection A in 2020 and has supported the corporate from idea to scientific improvement, underlining Germany’s power as a biotech innovation hub and its capacity to mobilise non-public capital for capital-intensive applied sciences.
“HTGF was one among our earliest traders and supported us in shaping Tubulis throughout its early life. Their renewed dedication on this spherical displays the continued partnership and shared perception in our mission to broaden the therapeutic potential of ADCs for sufferers worldwide,” stated Dr. Dominik Schumacher, CEO and Co-founder of Tubulis.
Dr. Frank Hensel, Principal at HTGF, added: “Our relationship with Tubulis has at all times been constructed on belief and a shared ambition to redefine oncology therapy. This newest spherical, supported by main international traders, validates the power of the platform and the group. We’re proud to proceed backing Tubulis because it enters a pivotal section of scientific improvement.”
Dr. Achim Plum, Managing Director at HTGF, stated: “Tubulis’ Collection C demonstrates that even extremely capital-intensive, disruptive applied sciences can entice the non-public funding wanted to deliver cutting-edge therapies to sufferers. For us at HTGF, Tubulis is a primary instance of how we function: we have interaction very early, typically earlier than an organization is based, and construct trusted relationships with distinctive groups. This story displays our perception in scientific excellence, entrepreneurial imaginative and prescient, and the impression that may be achieved when each come collectively. Congratulations to your entire Tubulis group on this excellent success.”
Tubulis’ breakthrough ADC applied sciences have positioned it as one among Europe’s most promising biotech gamers. By combining world-class science, scientific progress, and international investor confidence, the corporate continues to advance its mission of increasing the therapeutic potential of ADCs for most cancers sufferers worldwide.
